Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points

Rivista
SUPPORTIVE CARE IN CANCER
Autori
Rossi M, Gambino A, Cabras M, Alessio M, Fusco V
Citazione bibliografica
2021 Aug;29(8):4185-4186
DOI
10.1007/s00520-021-06100-4